# Exelixis, Inc.: financial statements, quarterly

EXEL · Nasdaq · CIK 939767 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 1

Pages: [Overview](/companies/exel.md) · [Financials](/companies/exel/financials.md) · [Filings](/companies/exel/filings.md) · [Insiders](/companies/exel/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/exel/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q4 FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [480 d](/filings/0000939767-26-000021.md) | [425](/filings/0000939767-25-000075.md) | [637](/filings/0000939767-25-000113.md) | [540](/filings/0000939767-25-000128.md) | [567 d](/filings/0000939767-26-000021.md) | [555](/filings/0000939767-26-000059.md) | [568](/filings/0000939767-26-000098.md) | [598](/filings/0000939767-26-000116.md) | [599 d](/filings/0000939767-26-000021.md) | [611](/filings/0000939767-26-000059.md) | [629](/filings/0000939767-26-000098.md) | [659](/filings/0000939767-26-000116.md) |
| Cost of revenue | $m | [21.8 d](/filings/0000939767-26-000021.md) | [21.3](/filings/0000939767-25-000075.md) | [17.7](/filings/0000939767-25-000113.md) | [17.3](/filings/0000939767-25-000128.md) | [20.0 d](/filings/0000939767-26-000021.md) | [19.2](/filings/0000939767-26-000059.md) | [19.5](/filings/0000939767-26-000098.md) | [18.6](/filings/0000939767-26-000116.md) | [26.5 d](/filings/0000939767-26-000021.md) | [20.0](/filings/0000939767-26-000059.md) | [20.7](/filings/0000939767-26-000098.md) | [26.2](/filings/0000939767-26-000116.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [245 d](/filings/0000939767-26-000021.md) | [228](/filings/0000939767-25-000075.md) | [211](/filings/0000939767-25-000113.md) | [223](/filings/0000939767-25-000128.md) | [249 d](/filings/0000939767-26-000021.md) | [212](/filings/0000939767-26-000059.md) | [200](/filings/0000939767-26-000098.md) | [199](/filings/0000939767-26-000116.md) | [213 d](/filings/0000939767-26-000021.md) | [200](/filings/0000939767-26-000059.md) | [212](/filings/0000939767-26-000098.md) | [209](/filings/0000939767-26-000116.md) |
| Selling, general and administrative | $m | [131 d](/filings/0000939767-26-000021.md) | [114](/filings/0000939767-25-000075.md) | [132](/filings/0000939767-25-000113.md) | [112](/filings/0000939767-25-000128.md) | [134 d](/filings/0000939767-26-000021.md) | [137](/filings/0000939767-26-000059.md) | [135](/filings/0000939767-26-000098.md) | [124](/filings/0000939767-26-000116.md) | [123 d](/filings/0000939767-26-000021.md) | [140](/filings/0000939767-26-000059.md) | [148](/filings/0000939767-26-000098.md) | [155](/filings/0000939767-26-000116.md) |
| Operating income | $m | [81.8 d](/filings/0000939767-26-000021.md) | [29.5](/filings/0000939767-25-000075.md) | [276](/filings/0000939767-25-000113.md) | [136](/filings/0000939767-25-000128.md) | [163 d](/filings/0000939767-26-000021.md) | [187](/filings/0000939767-26-000059.md) | [214](/filings/0000939767-26-000098.md) | [237](/filings/0000939767-26-000116.md) | [235 d](/filings/0000939767-26-000021.md) | [251](/filings/0000939767-26-000059.md) | [248](/filings/0000939767-26-000098.md) | [268](/filings/0000939767-26-000116.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [17.5 d](/filings/0000939767-26-000021.md) | [12.0](/filings/0000939767-25-000075.md) | [66.7](/filings/0000939767-25-000113.md) | [36.8](/filings/0000939767-25-000128.md) | [44.9 d](/filings/0000939767-26-000021.md) | [46.1](/filings/0000939767-26-000059.md) | [45.6](/filings/0000939767-26-000098.md) | [58.8](/filings/0000939767-26-000116.md) | [8.2 d](/filings/0000939767-26-000021.md) | [57.2](/filings/0000939767-26-000059.md) | [50.6](/filings/0000939767-26-000098.md) | [64.7](/filings/0000939767-26-000116.md) |
| Net income | $m | [85.5 d](/filings/0000939767-26-000021.md) | [37.3](/filings/0000939767-25-000075.md) | [226](/filings/0000939767-25-000113.md) | [118](/filings/0000939767-25-000128.md) | [140 d](/filings/0000939767-26-000021.md) | [160](/filings/0000939767-26-000059.md) | [185](/filings/0000939767-26-000098.md) | [194](/filings/0000939767-26-000116.md) | [245 d](/filings/0000939767-26-000021.md) | [210](/filings/0000939767-26-000059.md) | [212](/filings/0000939767-26-000098.md) | [218](/filings/0000939767-26-000116.md) |
| Diluted EPS | $ per share | not reported | [0.12](/filings/0000939767-25-000075.md) | [0.77](/filings/0000939767-25-000113.md) | [0.40](/filings/0000939767-25-000128.md) | not reported | [0.55](/filings/0000939767-26-000059.md) | [0.65](/filings/0000939767-26-000098.md) | [0.69](/filings/0000939767-26-000116.md) | not reported | [0.79](/filings/0000939767-26-000059.md) | [0.82](/filings/0000939767-26-000098.md) | [0.85](/filings/0000939767-26-000116.md) |
| Basic EPS | $ per share | not reported | [0.12](/filings/0000939767-25-000075.md) | [0.78](/filings/0000939767-25-000113.md) | [0.41](/filings/0000939767-25-000128.md) | not reported | [0.57](/filings/0000939767-26-000059.md) | [0.68](/filings/0000939767-26-000098.md) | [0.72](/filings/0000939767-26-000116.md) | not reported | [0.81](/filings/0000939767-26-000059.md) | [0.85](/filings/0000939767-26-000098.md) | [0.88](/filings/0000939767-26-000116.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [263](/filings/0000939767-25-000019.md) | [260](/filings/0000939767-24-000058.md) | [198](/filings/0000939767-24-000119.md) | [258](/filings/0000939767-24-000150.md) | [217](/filings/0000939767-26-000021.md) | [184](/filings/0000939767-25-000075.md) | [164](/filings/0000939767-25-000113.md) | [376](/filings/0000939767-25-000128.md) | [482](/filings/0000939767-26-000116.md) | [226](/filings/0000939767-26-000059.md) | [281](/filings/0000939767-26-000098.md) | [305](/filings/0000939767-26-000116.md) |
| Current assets | $m | [1,318](/filings/0000939767-25-000019.md) | [1,292](/filings/0000939767-24-000058.md) | [1,477](/filings/0000939767-24-000119.md) | [1,550](/filings/0000939767-24-000150.md) | [1,468](/filings/0000939767-26-000021.md) | [1,397](/filings/0000939767-25-000075.md) | [1,181](/filings/0000939767-25-000113.md) | [1,402](/filings/0000939767-25-000128.md) | [1,443](/filings/0000939767-26-000116.md) | [1,209](/filings/0000939767-26-000059.md) | [1,251](/filings/0000939767-26-000098.md) | [1,322](/filings/0000939767-26-000116.md) |
| Total assets | $m | [2,942](/filings/0000939767-25-000019.md) | [2,804](/filings/0000939767-24-000058.md) | [2,773](/filings/0000939767-24-000119.md) | [2,960](/filings/0000939767-24-000150.md) | [2,948](/filings/0000939767-26-000021.md) | [2,837](/filings/0000939767-25-000075.md) | [2,678](/filings/0000939767-25-000113.md) | [2,824](/filings/0000939767-25-000128.md) | [2,844](/filings/0000939767-26-000116.md) | [2,594](/filings/0000939767-26-000059.md) | [2,494](/filings/0000939767-26-000098.md) | [2,513](/filings/0000939767-26-000116.md) |
| Current liabilities | $m | [394](/filings/0000939767-25-000019.md) | [373](/filings/0000939767-24-000058.md) | [346](/filings/0000939767-24-000119.md) | [394](/filings/0000939767-24-000150.md) | [404](/filings/0000939767-26-000021.md) | [399](/filings/0000939767-25-000075.md) | [336](/filings/0000939767-25-000113.md) | [374](/filings/0000939767-25-000128.md) | [406](/filings/0000939767-26-000116.md) | [371](/filings/0000939767-26-000059.md) | [362](/filings/0000939767-26-000098.md) | [412](/filings/0000939767-26-000116.md) |
| Total liabilities | $m | [678](/filings/0000939767-25-000019.md) | [676](/filings/0000939767-24-000058.md) | [653](/filings/0000939767-24-000119.md) | [685](/filings/0000939767-24-000150.md) | [703](/filings/0000939767-26-000021.md) | [706](/filings/0000939767-25-000075.md) | [645](/filings/0000939767-25-000113.md) | [663](/filings/0000939767-25-000128.md) | [683](/filings/0000939767-26-000116.md) | [658](/filings/0000939767-26-000059.md) | [650](/filings/0000939767-26-000098.md) | [680](/filings/0000939767-26-000116.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,264](/filings/0000939767-26-000021.md) | [2,128](/filings/0000939767-25-000113.md) | [2,120](/filings/0000939767-25-000128.md) | [2,275](/filings/0000939767-25-000128.md) | [2,244](/filings/0000939767-26-000116.md) | [2,131](/filings/0000939767-26-000098.md) | [2,034](/filings/0000939767-26-000116.md) | [2,161](/filings/0000939767-26-000116.md) | [2,161](/filings/0000939767-26-000116.md) | [1,936](/filings/0000939767-26-000098.md) | [1,844](/filings/0000939767-26-000116.md) | [1,834](/filings/0000939767-26-000116.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q4 FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.6 d](/filings/0000939767-26-000021.md) | [68.8](/filings/0000939767-25-000075.md) | [120 d](/filings/0000939767-25-000113.md) | [271 d](/filings/0000939767-25-000128.md) | [240 d](/filings/0000939767-26-000021.md) | [211](/filings/0000939767-26-000059.md) | [49.0 d](/filings/0000939767-26-000098.md) | [290 d](/filings/0000939767-26-000116.md) | [334 d](/filings/0000939767-26-000021.md) | [252](/filings/0000939767-26-000059.md) | [308 d](/filings/0000939767-26-000098.md) | [280 d](/filings/0000939767-26-000116.md) |
| Capital expenditure | $m | [13.1 d](/filings/0000939767-26-000021.md) | [9.7](/filings/0000939767-25-000075.md) | [6.6 d](/filings/0000939767-25-000113.md) | [8.2 d](/filings/0000939767-25-000128.md) | [4.0 d](/filings/0000939767-26-000021.md) | [3.0](/filings/0000939767-26-000059.md) | [2.8 d](/filings/0000939767-26-000098.md) | [1.5 d](/filings/0000939767-26-000116.md) | [1.2 d](/filings/0000939767-26-000021.md) | [1.5](/filings/0000939767-26-000059.md) | [6.8 d](/filings/0000939767-26-000098.md) | [2.5 d](/filings/0000939767-26-000116.md) |
| Share repurchases | $m | [209 d](/filings/0000939767-26-000021.md) | [185](/filings/0000939767-25-000075.md) | [264 d](/filings/0000939767-25-000113.md) | [11.9 d](/filings/0000939767-25-000128.md) | [190 d](/filings/0000939767-26-000021.md) | [284](/filings/0000939767-26-000059.md) | [302 d](/filings/0000939767-26-000098.md) | [104 d](/filings/0000939767-26-000116.md) | [258 d](/filings/0000939767-26-000021.md) | [430](/filings/0000939767-26-000059.md) | [323 d](/filings/0000939767-26-000098.md) | [250 d](/filings/0000939767-26-000116.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [326](/filings/0000939767-24-000058.md) | [327](/filings/0000939767-24-000119.md) | [319](/filings/0000939767-24-000150.md) | [306](/filings/0000939767-25-000075.md) | [294](/filings/0000939767-25-000113.md) | [291](/filings/0000939767-25-000128.md) | [288](/filings/0000939767-26-000059.md) | [284](/filings/0000939767-26-000098.md) | [279](/filings/0000939767-26-000116.md) | [267](/filings/0000939767-26-000059.md) | [260](/filings/0000939767-26-000098.md) | [256](/filings/0000939767-26-000116.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 244,010,895 at 2026-10-19, from the cover of the [10-Q filed 2026-10-29](/filings/0000939767-26-000116.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:46 ET. No prices; not investment advice.